lymphocytes

[Nature Reviews Immunology] Scientists discuss novel latency-reversing agents targeting DCs as well as DC-based strategies to enhance the clearance of infected cells by CD8+ T cells and strategies to improve the killing activity of natural killer cells.

[Frontiers in Immunology] The authors explored the combination between zeste homolog 2 (EZH2) inhibitor and an agonist antibody targeting the T cell costimulatory receptor 4-1BB.

[Journal of Immunology] Through the engineering of an HLA-DR1 chimeric Ag receptor (CAR), the authors produced CD8+ CAR T cells that target CD4+ T cells in an Ag-specific manner and tested their ability to inhibit the development of autoimmune arthritis in a mouse model.

[Todos Medical, Ltd.] Todos Medical, Ltd. announced that it has entered into an exclusive European licensing & distribution agreement with T Cell Protect Hellas S.A. for a product based on its Tollovid® and Tollovid Daily™ 3CL protease inhibitor and immune support dietary supplements.

[Cancer Immunology Research] Investigators indicated that blocking C3aR signaling in natural killer (NK) cells increased NK-cell infiltration into the tumor microenvironment in mouse models and led to tumor regression.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators revealed that IκB kinase (IKK)-α in distinct endothelial cell (EC)-derived compartments was uniquely required to promote B cell homeostasis and lymph node (LN) development, and they established that lymphatic EC-intrinsic IKK-α was absolutely essential for LN formation.